Orphan Drugs in Oncology Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||274976|
This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will in many countries provide several years of marketing exclusivity if the product candidate is approved for the designated orphan indication. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of applying for marketing approval.
There are today 476 companies plus partners developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer. In addition, there are 15 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Orphan Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 422 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 404 out of the 407 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 79 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator